Based on ODYSSEY Outcomes and FOURIER, what are the findings and/or biologic risk features—Lp(a), for example—in patients managed in an interventional cardiology setting that would make you advocate for the use of PCSK9 inhibitors?

Based on ODYSSEY Outcomes and FOURIER, what are the findings and/or biologic risk features—Lp(a), for example—in patients managed in an interventional cardiology setting that would make you advocate for the use of PCSK9 inhibitors?

CLICK HERE FOR CME CREDIT

Based on ODYSSEY Outcomes and FOURIER, what are the findings and/or biologic risk features—Lp(a), for example—in patients managed in an interventional cardiology setting that would make you advocate for the use of PCSK9 inhibitors?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Phillipe Steg, MD

Phillipe Steg, MD

Professor of Cardiology Université Paris – Diderot, Sorbonne-Paris Cité Professor, National Heart and Lung Institute Imperial College, London, UK Director, Coronary Care Unit Hôpital Bichat Paris, France